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ABSTRACT Cooperation between the adenovirus EIA and
ElB oncogenes is required for transformation of primary qui-
escent rodent cells. Although expression of ElA alone will
stimulate cell proliferation suffit to initiate transformed
focus formation, proliferation fails to be sa and foci
degenerate. Coexpression of either the 19-kDa or 55-kDa E1B
oncoproteins with ElA permits high-frequency ransformation
by overcoming this cytotoxic response. Without E1B 19-kDa
protein expression, however, transformants remain susceptible
to induction of cell death. Rapid loss of viability is coincident
with nucleolytic cleavage of DNA in intranucleosomal regions
and chromatin condensation, hallmarks ofprogramed cell death
(apoptosis). Furthermore, overexpression of a known suppres-
sor of apoptosis, the Bd-2 protooncogene, can rescue E1A-
induced focus degeneration. Thus ElA-dependent stimuiation of
cell proliferation is accompanied by apoptosis and thereby
insuffiient to singly induce trnsformation. Hlg-fequency
transformation requires a second function encoded by the E1B
19-kDa protein to block apoptosis.
The adenovirus ElA proteins play an essential role in pro-
ductive viral infection and cooperate with the products of the
E1B oncogene to promote the oncogenic transformation of
primary rodent cells (1). The E1B gene encodes two distinct
tumor antigens, the 19-kDa and 55-kDa proteins, which are
both independently capable of promoting transformation in
cooperation with ElA (2-5). The function of the E1B 55-kDa
protein in transformation likely derives from a physical
association with the p53 tumor suppressor gene product (6),
whereas the function of the E1B 19-kDa protein in transfor-
mation has been unclear. In productively infected cells,
however, the E1B 19-kDa protein has a well-established
function in blocking DNA fragmentation (7-10) and prema-
ture death of the host cell (11, 12) induced by expression of
the ElA proteins (13-15). These cytotoxic effects of ElA
resemble induction of programed cell death or apoptosis and
suggested that the function ofthe E1B 19-kDa protein may be
inhibition of apoptosis (14).
In support of this idea, the E1B 19-kDa protein was found
to be a potent inhibitor of the cytotoxic action of tumor
necrosis factor a (TNF-a) or anti-Fas antibodies (16-18),
both ofwhich induce apoptosis (19, 20). In the case ofTNF-a,
the ability of the E1B 19-kDa protein to block DNA frag-
mentation and death was genetically inseparable from trans-
forming activity (18). The single event of suppressing apo-
ptosis may therefore account for TNF-a resistance and
transforming activity of the E1B 19-kDa protein. We have
examined the role of ElA and E1B in transformation of
primary rodent cells and found that ElA expression elicits a
cytotoxic response that resembles apoptosis. Coexpression
of E1B, predominantly the 19-kDa protein, or the human
Bcl-2 protooncogene with ElA mitigates the cytotoxic re-
sponse and rescues transformation.
MATERIALS AND METHODS
Primary Cell Transformation Assays. Kidneys were ex-
cised from 6-day-old Fischer rats (Taconic Farms), treated
with collagenase and dispase to produce a uniform cell
suspension, and transfected by electroporation as described
(14). Plasmid DNAs were linearized by restriction enzyme
digestion and 20 ug of total DNA (10-15 jg of each plasmid
with the remainder made up with denatured salmon sperm
DNA) per kidney was transfected. Transfected cells were
then plated in Dulbecco modified Eagle medium (DMEM)
with 5% fetal bovine serum and changed weekly. Plates were
fixed with methanol/acetone (1:1) for 15 min and stained with
20%o Giemsa in phosphate-buffered saline (PBS) for 20 min.
Viability Assays. Previously described transformed cell
lines (2) at low passage were plated at low density (1 x 105
cells per dish) in multiple 2.5-cm dishes in DMEM with 10%1b
fetal bovine serum. Once daily up to 12 days after plating the
cells were trypsinized and the viable cell number per plate
was determined by staining with Trypan blue.
DNA Fragmentation Assays. Transformed baby rat kidney
(BRK) cell lines were plated in 10-cm dishes and treated
essentially as described for viability assays. The culture
medium from all nine transformed BRK cell lines containing
most of the floating, predominantly dead cells was harvested
by low-speed centrifugation. Low molecular weight DNA
was extracted from the cell lines by the method of Hirt (21)
with minor modifications (7). Equal volumes of Hirt super-
natant fractions from BRK lines were analyzed by electro-
phoresis in a 1% agarose gel and visualized by ethidium
bromide staining. Ad5dl309 (22) DNA digested with HindIII
was used as molecular weight markers.
Ultrastructural Analysis. For electron microscopy the 55C
cell line was maintained in high or low serum for 24 hr as
described above and =5 x 105 cells were harvested, washed
in PBS, pelleted, and fixed in 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer (pH 7.3) overnight, followed by
postfixation with buffered 1% osmium tetroxide (pH 7.3) for
1 hr. Samples were embedded in Econ 812, sectioned, and
stained for 20 min in 2% aqueous uranyl acetate and for 2 min
in lead citrate. Grids were viewed on a JOEL 200EX electron
microscope.
Antibodies and Western Blotting. Cell extracts were pre-
pared from transformed BRK cell lines and Western blotting
was performed by standard procedures. Immune complexes
were visualized by the enhanced chemiluminescence method
Abbreviations: BRK, baby rat kidney; TNF-a, tumor necrosis factor
a.
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n). The monoclonal antibody directed against hu- into two distinct phases, distinguished temporally and by the
6C8, was previously described (23). Monoclonal differential requirements for ElA and E1B gene expression.
1c-2/100 directed against human Bc1-2 was gener- The first phase represents induction of cell proliferation and
Wided by David Mason (John Radcliffe Hospital, initiation of focus formation, which is exclusively ElA de-
.K.). pendent and E1B independent. The second subsequent phase
required to sustain proliferation is E1B dependent.
RESULTS ElA Induces Focus Degeneration in the Absence of E1B.
wression Is Sufficient for Initiation of Focus Forma- ElA expression is sufficient to promote the Go or G1 to S
ary BRK cell cultures prepared from 6-day-old transition and stimulate cellular DNA synthesis in quiescent
.s were used as a source of normal cells with which cells (26, 27). The ability of ElA to efficiently initiate
- the transforming activity of the adenovirus ElA proliferation and focus formation is consistent with these
yene-encoded proteins. These cells are quiescent observations. However, the failure of ElA to subsequently
y no significant levels of spontaneous transform sustain proliferation and the requirement for E1B gene prod-
1). Plasmids encodingElA under the direction of ucts for this function suggested that E1B functioned down-1romoter (pEA) and a series of E1B expression stream of ElA. When ElA-induced foci were examined
signed to express the 19-kDa protein (pCMV19K), microscopically during the E1B-dependent phase of trans-
a protein (pCMV55K), or an intact E1B gene formation, it was apparent that the absence of continued
B) (2, 24) were introduced and focus development transformed focus progression was due to induction of sig-
ored over time. In the initial 14 days, there was nificant levels of cell death (Fig. 2). Large numbers of highly
y little difference in the number of foci obtained refractile, nonviable cells (determined by an inability to
ansfection of the ElA gene alone or in conjunction exclude trypan blue) were observed associated with foci
gene (Fig. 1). As the E1B gene has no detectable derived from transfection of ElA alone, and foci underwent
in the absence of ElA (14, 25), ElA can degeneration (Fig. 2). Coexpression of ElA with the E1Bingability
..'.'...19-kDaprotein, either in the context of an intact E1B gene orus formation in an efficient manner that is inde-EuB HoweverninanthefEcA-inducednfocihfailitogrow the pCMV19K expression vector, abrogated all signs of cell'ElB. However, the ElA-induced foci fall to grow death, whereas coexpression of the E1B 55-kDa protein was[y in the following 2-week period. Eventually, less effective (Fig. 2). This indicated that the E1B 19-kDa
aese will give rise to ElA immortalized clones at protein may be increasing the proliferative capacity of ElA
after transfection (18). transformants by inhibiting cell death, perhaps by apoptosis.
on of Either ElB Protein Is Required for Sustained The possibility that the differential suppression of cell deathTransformed Foci. At 2-4 weeks after transfection, by the E1B 19-kDa and 55-kDa proteins during focus forma-
-derived foci fail to progress, the requirement for tion may be reflected in the growth characteristics of trans-
expression in transformation becomes strikingly formed BRK cell lines was investigated.
Coexpression of the ElB 19-kDa protein or an Transformed Cell Lines That Do Not Express the E1B
'gene with ElA dramatically enhances the prolif- 9-kDa Protein Are Susceptible to Cell Death. A series of
pacity of the transformants and >75% that form 19kaPoenAeSsptbeoCe DthAsrisf
.acit ofthetrainsforts and.>%. thatpform independently derived stable cell lines have been produced
e capable of sustaoing growt fig. 1). coexpres- from transfection ofBRK cells with ElA and E1B expression
E1B 55-kDa protein also facilitates continued vectors that differentially express the E1B proteins (2). These
butetoaesserextgentthansformatheo cankba prtei lines possess many characteristics of transformed cells andi reoreonc enirn o ton divded express comparable levels of ElA proteins. However, they
14 17 20 24 28 days differentially responded to growth to high-saturation density
-.I- or serum deprivation, conditions known to induce apoptosis
in other cell types (reviewed in ref. 28). Induction of cell
death in the different transformed cell lines upon growth from
low to high density was monitored in a viability assay (Fig.
_-
\ rcvi3).Cell lines that expressed the E1B 19-kDa protein (either
E1A+E1B or E1A+E1B 19-kDa transformants) maintained
1 ' ( ;'-,.",o;viability for at least 3 days after reaching saturation density
.0/$iz*(Fig. 3). In contrast, E1A+E1B 55-kDa transformants dem-
onstrated a pronounced and rapid loss of viability immedi-
ately after achieving saturation density (Fig. 3).
Expression of the E1B 19-kDa Protein Prevents Cell Death by
Apoptosis. Cell death can occur nonspecifically by necrosis,
which involves loss of membrane integrity and lysis, or by a
specific process called apoptosis or programed cell death (29).
, Am i; Ha*-*4gg~isFeaturesthat distinguish apoptosis from necrosis are the
* . ¢; 4*'* induction of nuclear DNA fragmentation in intranucleosomal
regions and chromatin condensation. By using these criteria,
dying E1A+ElB 55-kDa transformed cell lines were examined
4v,; A ._^\{ * *t~ * i . t for induction of apoptosis. Al nine transformed cell lines were
plated at low density and 3 days after reaching saturation
density, when the differential viability of the cell lines was
maximal (<50% in E1A+E1B 55-kDa lines and >95% in
E1A+E1B and E1A+E1B 19-kDa lines), degraded DNA was
vesue ofelA dued focudsfncormngat by E1B. Priary isolated by the method of Hirt (21). This procedure permits there transfected plasmids encodi ElA (pE1A) orE1G1ush
vectors that express exclusively the E1B 19-kDa quantitative recovery of low molecular weight DNA, either
)rotein (pCMV19K), the E1B 55-kDa (ElB55K) protein aegrahea or viral DANA, Aorexample, trom ngn moiecuiar), or an intact E1B gene (pCMVE1B) (2, 24). At the weight chromosomal DNA. DNA fragmentation with a char-
mes the plates were fixed and stained with Giemsa to acteristic "ladder" pattern indicative of intranucleosomal
14). cleavage events occurred in dead cells from all three
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ElA+ElB 55-kDa cell lines (Fig. 4 Upper). No low molecular
weightDNA was detectable in identically treated cell lines that
expressed the E1B 19-kDa protein (Fig. 4 Upper).
One of the E1A+E1B 55-kDa cell lines (55C) was exam-
ined at the ultrastructural level for a morphological indication
of apoptosis, chromatin condensation. In normal concentra-
tions of fetal bovine serum (10%o), where viability was high,
cells appeared ultrastructurally normal (Fig. 4 Lower Left)
and not substantially different from E1A+ElB transformants
(data not shown). Under conditions of serum deprivation
(0.1% for 24 hr), where viability was low, cells frequently
possessed large masses of condensed chromatin (Fig. 4
Lower Right). Thus, expression of the E1B 19-kDa protein
during oncogenic transformation is required to suppress the
induction of apoptosis.
Cooperation Between EMA and BcI-2. The Bcl-2 protoon-
cogene was identified at a site of chromosomal translocation
E1A+EIB 55K EIA+E1B
FIG. 2. Transformed focus degeneration in
the absence of E1B 19.kDa gene expression.
Foci from a BRK transformation experiment
as described in the legend to Fig. 1 were
* photographed with a Nikon inverted-phase
microscope in the third week following elec-t-07;; dd bur trSsoporton. (x25 *)
in human B-cell lymphoma (30-32). Its overexpression in
certain hematopoietic cell lines results in the suppression of
apoptosis (23, 33, 34). Moreover, transgenic mice bearing a
Bcl-2-Ig minigene progress to monoclonal lymphoma (35).
However, although Bcl-2 is highly effective in blocking many
apoptotic pathways, others have been noted to be indepen-
dent (34, 36). To determine whether ElA-related apoptosis
represents a Bcl-2-dependent pathway, we examined com-
plementation between ElA and the BcI-2 gene product in
BRK transformation assays.
Neither Bcl-2 construct produced significant focus forma-
tion when transfected alone or with the E1B 19-kDa gene
(Fig. 5). BcI-2 transfection, however, did enhance focus-
forming efficiency of ElA by 4-fold (Fig. 5). BcI-2 was less
effective at stimulating focus formation than either the E1B
19-kDa or 55-kDa gene products (Fig. 5). This may reflect the
use of the human and not rat Bcl-2 gee, or perhaps BcI-2
EIA+EIB 19K
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FIG. 3. Expression of the E1B 19-kDa protein is required to maintain transformed cell viability at high cell density. Independent, stable,
transformed BRK cell lines expressing E1A+E1B 55-kDa (Left), E1A+E1B (Center), andE1A+E1B 19-kDa (Right) proteins (2) were monitored
for viability by trypan blue exclusion over time. Actual viable cell numbers are plotted (x 1O-5) versus days post plating.
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FIG. 4. Transformed cell lines that lack the E1B 19-kDa protein
die by apoptosis. (Upper) Induction of DNA fragmentation in
E1A+E1B 55-kDa but not E1A+E1B or E1A+E1B 19-kDa trans-
formed cell lines. The indicated transformed BRK cell lines were
grown as described in the legend to Fig. 3 and at day 8, 3 days after
reaching maximum density when viability of the E1A+E1B 55-kDa
transformants was low, the integrity of the chromosomal DNA was
determined (21). Marker, size markers (X10-3 base pairs). (Lower)
Ultrastructural appearance of E1A+E1B 55-kDa cell line 55C fol-
lowing induction of cell death by serum deprivation. (Left) Cells at
low density maintained in high serum (10%) (x2500). (Right) Cells at
low density maintained in low serum (0.1%) for 24 hr. (x 1500.)
Nuclei with condensed chromatin (CC) are indicated. (Bar = 1 ,um.)
function is less optimal in kidney epithelial cells than lym-
phoid cells. Alternatively, Bcl-2 may substitute for only a
portion of E1B 19-kDa protein effects in blocking apoptosis.
Four stable transformed cell lines were derived from ElA
and Bcl-2 cooperation assays and the level of expression of
the human Bcl-2 protein was determined by Western blotting
with human specific Bcl-2-specific monoclonal antibodies
6C8 and Bcl-2/100. These antibodies do not crossreact with
the endogenous rat protein and consequently no Bcl-2 protein
product is demonstrable in the E1A+E1B transformed rat
lines (Fig. 5, lane 5). In contrast, all four ElA+SFFV Bcl-2
FIG. 5. Cooperation between Bcl-2 and ElA. (Upper) Primary
BRK cells were transfected with the indicated plasmidDNAs and the
frequency of focus formation was determined after 28 days in a
standard focus assay. Growth to a focus diameter 25 mm was used
as a criterion for focus formation. The human Bcl-2 plasmid expres-
sion vectors Bcl-2SFFV and Bcl-2MHC have been described (23). A
compilation of data from three independent experiments is shown.
(Lower) Western blot of stable BRK cell lines derived from a
standard focus assay probed with a monoclonal antibody directed
against human Bcl-2 (6C8). Similar results were obtained with the
Bcl-2/100 monoclonal antibody (data not shown). For each line equal
amounts of protein (20 pg) were analyzed. Lanes 1-4, four indepen-
dent lines derived from transfection with the ElA and Bcl-2SFFV
plasmids: lane 5, E1A+E1B transformed cell line 4D (ref. 2), which
lacks the human Bcl-2 gene; lanes 6-8, three independent lines
derived from transfection of ElA, Bcl-2SFFV, and CMV19K ex-
pression vectors. The position of the Bcl-2 protein is indicated.
transformants expressed the human Bcl-2 protein (Fig. 5,
lanes 1-4). The level of expression of Bcl-2 in these trans-
formed rat kidney lines was comparable to that in a human
lymphoid line (Jurkat) where Bcl-2 is highly expressed (data
not shown). Transfection of the E1B 19-kDa expression
vector with EMA and Bcl-2 appears to have removed the
selective pressure for Bcl-2 expression in the focus assay,
and these stable transformants did not display detectable
human Bcl-2 protein (Fig. 5, lanes 6-8). Therefore, although
Bc1-2 can cooperate with EMA in a transformation assay it
does not appear to be as effective as the E1B 19-kDa protein.
DISCUSSION
Induction of apoptosis by EMA and its inhibition by the E1B
19-kDa protein offer an explanation not only for the response
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00
i
Proc. Natl. Acad. Sci. USA 89 (1992)
of primary rodent cells to transformation reported here but
also for phenotypes displayed by ElA and E1B mutant
adenoviruses in productively infected human cells. The ma-
jor, striking consequence following infection with an E1B
19-kDa mutant virus is the fragmentation of host cell chro-
mosomal DNA (deg phenotype) (7-10). DNA fragmentation
is accompanied by cytocidal effects (cyt phenotype), prema-
ture death of the host cell, and impaired virus yield (11, 12).
The main function of the E1B 19-kDa protein is thus to
maintain host cell viability during infection by preventing the
induction of cell death. Virus production is thereby maxi-
mized (15).
Suppression of apoptosis may provide an additional ad-
vantage by producing resistance to cytotoxic cytokines and
other toxic immunological responses to viral infection. This
may be particularly important in lymphoid cells, which are
acutely susceptible to apoptosis and are infected by adeno-
viruses in vivo, and may explain why the adenovirus E1B
19-kDa protein (16-18) as well as the E3 gene products
(37-40) produce resistance to TNF-a. Emerging evidence
indicates that the selective advantage in virus propagation
that suppression of apoptosis provides is harbored by anal-
ogous functions encoded by other viruses (41, 42). Thus the
E1B 19-kDa protein possesses the capacity to counteract
three independent inducers of apoptosis, ElA, TNF-a, and
anti-Fas antibodies. Adenovirus can thereby evade an intrin-
sic cell suicide response to viral infection and potentially host
immune surveillance defense mechanisms.
Unfortunately, the mechanism by which apoptosis is either
induced or suppressed is not known, although the importance
of its suppression in carcinogenesis is becoming increasingly
apparent (43). Overexpression of the wild-type but not mu-
tant tumor suppressor gene product p53 has been shown to
result in apoptosis in a myeloid leukemic cell line (44). The
ElA proteins have been shown to induce the accumulation of
p53 in some circumstances (45), but whether TNF-a does the
same, and p53 represents the universal mediator of pro-
gramed cell death, remains to be determined. It is interesting
to note that the E1B 55-kDa protein that binds to and
presumably sequesters p53 (6) can partially overcome apo-
ptosis triggered by ElA. This suggests that disposing of p53
is not completely sufficient to block apoptosis and a second
function provided by the E1B 19-kDa protein is required.
Alternatively, p53 sequestration by the E1B 55-kDa protein
may not be complete, which suggests that E1B 19-kDa
protein may contribute to p53 elimination.
Another mechanism for apoptosis suppression involves the
Bc1-2 protooncogene. Overexpression of Bc1-2 will block
apoptosis, thereby extending the lifespan of B cells and
promoting transformation (23, 46). We report here that Bcl-2
can complement ElA in cooperation assays in an analogous
fashion to the E1B gene. Latent membrane protein 1 (LMP-1)
of Epstein-Barr virus can facilitate viral latency and onco-
genic transformation by elevating levels of Bc1-2 to inhibit
apoptosis (42). The E1B 19-kDa protein apparently encodes
a similar function that confers an advantage to adenovirus
survival and facilitates oncogenic transformation. The mech-
anism utilized by the E1B 19-kDa protein differs, however,
from LMP-1, as levels of Bc1-2 protein are not altered by E1B
19-kDa expression in human cells, which are resistant to
apoptosis (unpublished observations). Initiation of a chain of
events may be required to induce apoptosis, the individual
components of which are potentially susceptible to interven-
tion by viral gene products. Apoptosis may represent a cell
suicide response to deregulation of cell growth that is tar-
geted for inactivation by transforming proteins ofDNA tumor
viruses.
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